Drug intelligence / Profile preview

AGX-509

Development stage: Preclinical
Lead developer: AgonOx
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AGX-509 is an investigational T-cell receptor (TCR) engineered T-cell therapy being developed by AgonOx. This cell-based immunotherapy involves the identification of tumor-reactive TCRs which are then used to genetically engineer T cells to specifically recognize and eliminate cancer cells. Unlike CAR-T therapies that target surface antigens, TCR-based therapies like AGX-509 can recognize intracellular tumor-associated antigens presented by MHC molecules, potentially offering a broader range of targets in solid tumors. The program is part of AgonOx's pipeline focused on leveraging the specificity of the immune system to treat advanced malignancies.

Other names: AgonOx tumor-reactive TCR-cell therapy

Beyond the preview

Go deeper on AGX-509.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGX-509.

Explore the full profile